A major breakthrough for Canadians living with severe allergies has arrived as Health Canada has approved the country’s first needle-free emergency treatment for anaphylaxis — a nasal spray called neffy.
The approval marks a significant shift in allergy care, giving families, schools and individuals a new option beyond traditional auto-injectors such as EpiPen. For many Canadians who fear needles or hesitate to use injectable devices in emergencies, the new spray could be life-changing.
Distributed in Canada by ALK Canada, the two-milligram spray has been approved for adults and children weighing at least 30 kilograms, or approximately 66 pounds. The company says it could become available as early as this summer.
Medical experts say the importance of the decision goes far beyond convenience. In a severe allergic reaction, speed matters. Symptoms can escalate quickly and may affect breathing, blood pressure and the ability to swallow. Having a simpler and more accessible treatment could mean faster action in critical moments.
Doctors note that one of the biggest challenges with current injectors is hesitation. Some people delay treatment because they are unsure whether symptoms are serious enough, while others are anxious about using a needle. A nasal spray may help remove those barriers and encourage quicker response when every second counts.
The new treatment also offers practical benefits. It is smaller than many injectors, easier to carry, and can tolerate a broader range of temperatures. That matters for busy families, students, travellers and workers who need emergency medication close at hand throughout the day.
Anaphylaxis is commonly triggered by food allergies, insect stings such as bees, and certain medications. But specialists say allergies can develop at any stage of life, even in people who previously had no known reactions. As reports of severe allergies continue to rise, having more than one emergency treatment option becomes increasingly important.
The arrival of neffy does not replace existing injectors overnight, but it gives Canadians something many have long wanted: choice. It also helps reduce risk during supply shortages or backorders that have periodically affected allergy medications.
For households managing life-threatening allergies, this approval represents more than a new product. It is peace of mind, added preparedness and a reminder that innovation in health care can make everyday life safer for thousands of Canadians.